HHS Ends Federal Medicaid and CHIP Funding for Transgender Care for Minors

HHS Ends Federal Funding for Transgender Medical Procedures on Minors

The U.S. Department of Health and Human Services (HHS), through the Centers for Medicare & Medicaid Services (CMS), has finalized a rule that blocks federal Medicaid and Children’s Health Insurance Program (CHIP) funds from paying for a set of medical procedures on minors that the department labels “sex‑rejecting.” The banned interventions include puberty blockers, cross‑sex hormones, and surgical operations. The change, which was announced on August 11, 2026, implements an administration priority to end taxpayer support for what officials describe as experimental and irreversible treatments.

“Today, we are ending federal taxpayer funding for sex‑rejecting procedures on children,” HHS Secretary Robert F. Kennedy, Jr. said in the announcement. “These interventions carry serious risks and can cause irreversible harm.” CMS Administrator Dr. Mehmet Oz added that the move follows the science and protects children from potentially permanent damage, including infertility, impaired sexual function, diminished bone density, and altered brain development.

The rule includes a six‑month tapering period—running from the effective date—during which federal funds will remain available for children already receiving hormone therapy, allowing a managed transition. Crucially, the rule does not affect coverage of mental health services under Medicaid’s Early and Periodic Screening, Diagnostic, and Treatment (EPSDT) provisions, meaning that counseling and other mental health supports for eligible children remain fully covered.

The Evidence Review and the Real‑World Impact of the Funding Cut

The Evidence Behind the Policy Shift

CMS’s decision rests on an internal HHS review of national and international research that the department says revealed significant evidence gaps and serious safety concerns. The agency points specifically to the United Kingdom’s Cass Report, which concluded that the evidence base for youth gender medicine is weak, and notes that several countries and U.S. states have moved to restrict these procedures for minors. The announcement also highlights a recent clarification by the American Society of Plastic Surgeons, which called for careful consideration in performing such surgeries on adolescents, signaling a shift within parts of the medical community.

Impact on Transgender Youth and Families

The immediate practical effect is that families relying on Medicaid or CHIP will lose a major funding source for hormone therapy and puberty blockers if they have not already completed the six‑month taper. This will likely force some families to pay out‑of‑pocket or forgo treatment, potentially deepening health inequities among low‑income transgender adolescents. For the roughly 650,000 Medicaid‑enrolled children estimated to identify as transgender, the rule could disrupt established care plans, even if mental health coverage remains intact.

State‑Level and Legal Implications

The federal prohibition does not prevent states from using their own funds to cover the procedures. Several states have already enacted laws that require or permit Medicaid coverage of gender‑affirming care, setting up potential conflicts between state policy and federal rules. Legal challenges are widely expected, with advocacy groups likely to seek preliminary injunctions. If courts block the rule, the implementation timeline could quickly unravel, creating ongoing uncertainty for state Medicaid directors and healthcare providers.

What Families, Providers, and States Should Know About the New Rule

• Families with a child currently on hormone therapy should confirm the exact start date of the tapering period with their state Medicaid agency and plan for the transition to non‑federal funding or a medically supervised discontinuation over the next six months.
• State Medicaid programs that wish to continue covering these procedures can use state‑only dollars; officials should immediately assess budget and legal authority to do so.
• Healthcare providers must update billing systems and patient communications to reflect the coverage change and advise families on the mental health services that remain available without disruption.
• Legal challenges are almost certain; families and providers should watch for court‑ordered delays or stays that could temporarily preserve coverage while litigation proceeds.
• Mental health parity is unchanged: EPSDT ensures full access to counseling and related services, which can be crucial for families navigating the policy shift.